Skip to main content
OpenTrials
Completed

NCT Number: NCT02538211

The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses

The purpose of this study is to evaluate if the intestinal microbiota influences rotavirus vaccine immune responses in healthy adult volunteers.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study will alter the intestinal microbiota in healthy adults using antibiotics and subsequently measure immune reactions to the rotavirus vaccine (Rotarix), the tetanus vaccine and the pneumococcal vaccine (Pneumo23).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, as determined by a responsible physician, based on a medical evaluation including medical history, physical examination and laboratory tests carried out within 28 days prior to starting antibiotics (day -98). A subject with a clinical abnormality or laboratory parameter outside the reference range may be included if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
  • Male between 18 and 35 years of age, inclusive at the time of signing the informed consent
  • Capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form
  • Normal defecation pattern (defined as ≤3x/ day and ≥3x/week)

Exclusion criteria

  • Subject has had a major illness in the past 3 months or any significant chronic medical illness that the investigator would deem unfavorable for enrollment, including inflammatory diseases.
  • Subject with any history of immunodeficiency
  • Subjects with a history of any type of malignancy
  • Subject with a history of thrombocytopenia or bleeding disorder
  • Subject has a past or current gastrointestinal disease which may influence the gut microbiota
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • History of alcoholism and/or drinking more than an average of 5 units of alcohol per day
  • The subject has received an investigational product within three months of day 0 of the current study

Treatment and study plan

Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine

Biological

All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.

Other names: RotarixTM, Pneumo 23

Primary outcomes

  1. Height of serum anti-rotavirus Immunoglobulin A (IgA) response

    Time frame: 28 days post-vaccination

    Geometric Mean Concentration (GMC)

Secondary outcomes

  1. Time to positivity for serum anti-rotavirus Immunoglobulin A (IgA) and G (IgG) response

    Time frame: day 0 through day 28 post vaccination

    (days)

  2. Change in pre and post-vaccination anti-rotavirus (anti-RV) serum neutralizing antibodies measured by Geometric Mean Concentration (GMC)

    Time frame: 28 days post-vaccination

  3. Change in pre and post-vaccination anti-RV serum IgG response measured by Geometric Mean Concentration (GMC)

    Time frame: day 0 through day 28 post vaccination

  4. Change in serum tetanus toxoid IgG response, measured as pre and post vaccination titer (international units/mL) ratio

    Time frame: day 0 through day 28 post vaccination

  5. Change in serum pneumococcal poly-saccharide-specific IgG for all vaccine strains , measure in pre and post vaccination titer (micrograms/mL) ratio

    Time frame: day 0 through day 28 post vaccination

  6. Composition of the fecal micro biome before and after antibiotics and between groups measured by the HITChip and bacterial 16S rRNA sequencing

    Time frame: day -9 and day 0 pre vaccination

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Collaborators

  • Centers for Disease Control and Prevention
  • Wageningen University and Research

Registry information

Acronym: Rota-biome

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Sep 2, 2015
Registry last updated
Jul 25, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.